BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23%...
BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23%...
BioAtla Presented Data Characterizing Mutated KRAS Genotype And Clinical Outcomes In Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, A CAB-AXL-ADC, At The IASLC 2024; 1-Year OS Was 58% For Patients With NSCLC Expressing MKRAS Versus 23% For WtKRAS
BioAtla在2024年的IASLC上公佈了描述晚期非小細胞肺癌患者的突變KRAS基因型和臨床療效的數據；表達MKRAS的非小細胞肺癌患者的1年期操作系統爲58％，WTKRAS的非小細胞肺癌患者爲23％
Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS)
與接受治療難治性非小細胞肺癌 (NSCLC) 表達野生型 KRAS (WTKRA) 的 Mec-V 治療患者相比，接受治療難治性非小細胞肺癌 (NSCLC) 表達突變KRAS (MKRA) 的患者中位總存活率 (OS) 有所提高
One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS
表達 mKRA 的非小細胞肺癌患者的一年期操作系統爲 58%，而 WTKRA 的患者爲 23%
Mec-V antitumor activity observed across 9 different mKRAS variants
在 9 種不同的 MKRA 變體中觀察到 Mec-V 抗腫瘤活性
Strong association of AXL expression by mKRAS NSCLC confirmed
MKRA NSCLC 與 AXL 表達的密切關聯得到證實
SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, presented a poster entitled "Characterization of Mutated KRAS Genotype and Clinical Outcomes in Patients With Advanced NSCLC Treated With Mecbotamab Vedotin, a CAB-AXL-ADC" at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting on December 14, 2024.
聖地亞哥，2024年12月16日（GLOBE NEWSWIRE）——專注於開發用於治療實體瘤的條件活性生物製劑（CAB）抗體療法的全球臨床階段生物技術公司BioAtla, Inc.（納斯達克股票代碼：BCAB）發佈了一張題爲 「用Mecbotamab Vedotin治療的晚期非小細胞肺癌患者的突變KRAS基因型和臨床預後特徵的海報 Cab-axl-ADC」 在2024年12月14日舉行的IASLC 2024基礎與轉化科學熱門話題會議上。